Tenofovir Alafenamide Fumarate: Advancing HIV Treatment and Research
Discover the benefits of Tenofovir Alafenamide Fumarate, a key player in modern antiviral therapies.
Inquire NowProduct Core Value
Tenofovir Alafenamide Fumarate
Tenofovir Alafenamide Fumarate (TAF), also identified as GS-7340, is a highly effective prodrug of tenofovir, pivotal in the fight against HIV-1 infection and Hepatitis B. Its innovative formulation allows for higher intracellular concentrations of tenofovir, leading to enhanced antiviral efficacy and a more favorable safety profile compared to older tenofovir formulations.
- Explore the advantages of TAF for HIV treatment: Understand how TAF plays a crucial role in managing HIV infection.
- Learn about TAF's role in Hepatitis B therapy: Discover its application in treating chronic Hepatitis B.
- Understand the prodrug mechanism: Learn how TAF is converted to its active form for maximum benefit.
- Compare TAF with tenofovir disoproxil fumarate (TDF): Gain insights into the improved safety and efficacy profile of TAF.
Key Advantages of Tenofovir Alafenamide Fumarate
Enhanced Antiviral Efficacy
TAF delivers higher intracellular tenofovir diphosphate (TFV-DP) levels, boosting antiviral activity against HIV.
Improved Safety Profile
Lower serum tenofovir levels mean reduced exposure to vital organs like kidneys and bones, minimizing potential adverse effects.
Convenient Administration
As an orally administered prodrug, TAF offers ease of use in treatment regimens.
Key Applications
HIV Treatment
TAF is a cornerstone in many combination therapies for the treatment of HIV-1 infection, offering improved outcomes.
HIV Prevention (PrEP)
In specific combinations, TAF contributes to pre-exposure prophylaxis (PrEP) for HIV prevention.
Hepatitis B Treatment
TAF is also approved for the treatment of chronic Hepatitis B virus infection.
Pharmaceutical Research
Its development represents significant progress in antiviral drug design, making it a subject of ongoing research.